TGF-β1–induced expression of human Mdm2 correlates with late-stage metastatic breast cancer

S Araki, JA Eitel, CN Batuello… - The Journal of …, 2010 - Am Soc Clin Investig
S Araki, JA Eitel, CN Batuello, K Bijangi-Vishehsaraei, XJ Xie, D Danielpour, KE Pollok
The Journal of clinical investigation, 2010Am Soc Clin Investig
The E3 ubiquitin ligase human murine double minute (HDM2) is overexpressed in 40%–
80% of late-stage metastatic cancers in the absence of gene amplification. Hdm2 regulates
p53 stability via ubiquitination and has also been implicated in altering the sensitivity of cells
to TGF-β1. Whether TGF-β1 signaling induces Hdm2 expression leading to HDM2-mediated
destabilization of p53 has not been investigated. In this study, we report that TGF-β1–
activated SMA-and MAD3 (Smad3/4) transcription factors specifically bound to the second …
The E3 ubiquitin ligase human murine double minute (HDM2) is overexpressed in 40%–80% of late-stage metastatic cancers in the absence of gene amplification. Hdm2 regulates p53 stability via ubiquitination and has also been implicated in altering the sensitivity of cells to TGF-β1. Whether TGF-β1 signaling induces Hdm2 expression leading to HDM2-mediated destabilization of p53 has not been investigated. In this study, we report that TGF-β1–activated SMA- and MAD3 (Smad3/4) transcription factors specifically bound to the second promoter region of HDM2, leading to increased HDM2 protein expression and destabilization of p53 in human cancer cell lines. Additionally, TGF-β1 expression led to Smad3 activation and murine double minute 2 (Mdm2) expression in murine mammary epithelial cells during epithelial-to-mesenchymal transition (EMT). Furthermore, histological analyses of human breast cancer samples demonstrated that approximately 65% of late-stage carcinomas were positive for activated Smad3 and HDM2, indicating a strong correlation between TGF-β1–mediated induction of HDM2 and late-stage tumor progression. Identification of Hdm2 as a downstream target of TGF-β1 represents a critical prosurvival mechanism in cancer progression and provides another point for therapeutic intervention in late-stage cancer.
The Journal of Clinical Investigation